US FDA Approves Novartis Skin Treatment Drug Cosentyx
The U.S. FDA has approved Novartis’ drug Cosentyx for treating moderate to severe hidradenitis suppurativa, a chronic inflammatory skin condition.
There have been multiple accounts created with the sole purpose of posting advertisement posts or replies containing unsolicited advertising.
Accounts which solely post advertisements, or persistently post them may be terminated.
The U.S. FDA has approved Novartis’ drug Cosentyx for treating moderate to severe hidradenitis suppurativa, a chronic inflammatory skin condition.